

Supplemental Table 1. Comparison of observed and simulated bevacizumab plasma concentrations after infusion of 5 mg/kg bevacizumab every other week

Concentration	<i>N</i>	Percentile	Observed value	Simulated value	Deviation
End of 1 st infusion	14	25 th	84.2	104 (83.7–122)	22.9
of Cycle 1		50 th (median)	119	123 (104–144)	3.49
		75 th	159	147 (122–175)	-7.85
24 h after 1 st infusion of Cycle 1	14	25 th	59.9	79.3 (63.5–95.0)	32.3
		50 th (median)	94.5	95.2 (79.7–112)	0.745
		75 th	119	113 (94.8–134)	-5.19
Shortly before 2 nd infusion of Cycle 1	13	25 th	15.7	19.5 (12.4–27.0)	24.5
		50 th (median)	20.5	26.2 (19.4–32.9)	27.9
		75 th	24.5	33.5 (25.8–42.1)	36.8
End of 2 nd infusion of Cycle 1	14	25 th	111	124 (102–147)	12.0
		50 th (median)	154	149 (127–175)	-3.85
		75 th	168	176 (150–208)	5.08
24 h after 2 nd infusion of Cycle 1	14	25 th	82.6	100 (83.3–119)	21.5
		50 th (median)	104	120 (103–140)	16.1
		75 th	122	144 (122–167)	17.9
Shortly before 2 nd infusion of Cycle 4	1	50 th (median)	58.7	46.1 (14.7–91.0)	-21.5
24 h after 2 nd infusion of Cycle 4	2	50 th (median)	239	204 (143–274)	-14.8

Shortly before 1 st infusion of Cycle 5	2	50 th (median)	70.1	62.1 (31.2–105)	-11.4
End of 1 st infusion of Cycle 5	2	50 th (median)	182	201 (145–276)	10.4
